catalyst calendar
BIOVIE INC · Data as of 2026-10-27
Fall 2026
We have corresponded with the FDA to request an End-of-Phase 2 Meeting and look forward to discussing our proposed trial design with the FDA later this fall. We anticipate receiving formal written feedback before year-end.Source filing
Nov 5
Dr. Penelope Markham, BioVie's Senior Vice President and Program Lead for Long COVID, will share results from the Company's Phase 2 ADDRESS-LC trial evaluating bezisterim for the treatment of the neurological symptoms of Long COVID at the "Recent Insights from Long COVID Clinical Trials" Panel Discussion on Thursday, November 5, being held from 9:10 –10:10 a.m. ET.Source filing